Default company panoramic image
Ira 20004

Parabiotic Research & Development Corp.

Parabiotic is developing combination antibiotic/probiotic drug products encapsulated together for the treatment of inflammatory bowel and infectious diseases.

  • Stage Product In Development
  • Industry Biotechnology
  • Location New York City, NY, USA
  • Currency USD
  • Founded January 2008
  • Employees 2
  • Incorporation Type S-corp
  • Website

Company Summary

Parabiotic's focus is on the development of innovative combination antibiotic/probiotic drug products for the treatment of Inflammatory Bowel disease-ulcerative colitis and Crohn's disease. The company's patented lead product, PB-1, is the first of a new class of targeted combination drugs that will address underlying suspected causal factors in the initiation of disease- as opposed to being merely symptom managing.